Navigation Links
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Date:5/21/2008

nefits.

Investor Q&A Session

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will join United Therapeutics' senior management in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

About Remodulin

Remodulin is indicated for the treatment of PAH in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

Remodulin is indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan(R); the risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information

Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Remodulin is contraindicated in patients with hypersensitivity to Remodulin, its ingredients, or similar drugs. Remodulin is a potent vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
4. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
6. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
7. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...oncept of Other Product - Company,s Bioabsorbable ... HONG KONG, Oct. 6 /- Data from mult...ing stent, OrbusNeich,s Genous Bio-engineered R,st...ter Cardiovascular,Therapeutics symposium, TCT 200...Ph.D., of the Academic Medical Center in,Amsterdam...
(Date:10/3/2008)...IK, Iceland, Oct. 3 /- deCO...iling of an investigational new drug,(IND) applica... modulator,of phosphodiesterase 4 (PDE4), with the...nd is being developed as a new and potentially saf...nd cognitive deficits associated,with Alzheimer,s ...
(Date:10/2/2008)...October 2 /- Pharmaleads has obtained...horization to perform a single,ascending dose Phas...eatment of neuropathic pain., Neuropathic pain is...,prevalence in the world,s population of up to 6%,...auses such as shingles, herpes, diabetes,antivira...
(Date:10/2/2008)... England, October 2 /- Circassia Ltd,...the fields of allergy and critical,care, today ann...udy of its,ToleroMune(R) technology in the field o...s achieved in an earlier phase II study, which dem...oleroMune approach to allergy,desensitization., I...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 1Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 3New study finds biodiversity conservation secures ecosystem services for people 1471 1New study finds biodiversity conservation secures ecosystem services for people 1471 2Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 1Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 2CME LLC Restructures Announces Its New Executive Management Team 2074 1CME LLC Restructures Announces Its New Executive Management Team 2074 2
... Tolerance Support Development,of Omega DUROS Cont...2, 2007 /PRNewswire/ -- Intarcia,Therapeutics, Inc...ay announced final results from a Phase 2 study of...atment-naive patients,with genotype 1 chronic hepa...eron in combination with ribavirin is well tolerat...
...11, 2007 (PRIME NEWSWIRE) --,Hana Biosciences (Nas...advancing cancer care, will present preclinical da...the American Association,for Cancer Research 100th...California. , Abstract No. 2210: "Combining talotr...ll lung cancer (NSCLC) athymic nude,mice xenograft...
Other Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 2Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 3
(Date:10/6/2008)... special supplement of the Oct. 15,journal Cancer ...,middle-income countries to implement breast cance...ease among women worldwide., "Guidelines for Inte...mentation" developed by the Breast Health Global I...rce allocation -- based on countries,overall econ...
(Date:10/6/2008)...ecently posted detailed information on its Cimzia ...us side effects caused by the drug and its family ...l side effects are the development of fatal infect... child patients. , Denver...ber one resource for everything and anything legal...
(Date:10/6/2008)...-based civil litigation and criminal defense firm ...ury awarded $3.2 million to plaintiff earlier this...land ((Lexis Nexis) October 6, 2008 -- Attorneys i..., Murtha & Psoras] have successfully resolved ...nd welder who was awarded more than $3 million by ...
(Date:10/5/2008)... help detect serious bacterial infections (SBIs) l...ctions in young infants who come to the emergency ...se. Researchers at Children,s Hospital Boston, col... University, show that a new diagnostic marker cal...h risk for SBIs while potentially reducing unneces...
Breaking Medicine News(10 mins):Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:New test could help catch serious infections in babies 2
...ys at a Czech farm where the potentially lethal H5... been slaughtered, officials said on Friday. "All...process is underway for the smaller flocks in the ...all," Czech veterinary services spokesman Zbynek S...
...nned in virtually all public places in Slovenia, a...er 18 banned, under legislation adopted Friday by ...n August, amend for a third time Slovenia's origin...adopted in 1996. Smoking will be banned in all pub...
...nfected almost 20,000 people in Vietnam in the fir...e than in the same period last year, the health mi...alls have been blamed for the nearly 15 percent ri...squito-borne disease, which have been concentrated...
... adults have never had sex in their lives, and the...n-Americans, according to an official survey out o... 20-59 years have had sex, with the age group 20-2...1 percent)," the Center for Disease Control and Pr...
Other Medicine News:
Suture retriever forceps
Knot pusher/suture retriever
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture.
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand
Medicine Products: